Ananda Developments plc (AQSE: ANA), a company whose ambition is to be a leading provider of
cannabinoid-based medicines for the treatment of chronic, complex inflammatory pain conditions,
is pleased to announce that its wholly owned subsidiary MRX Medical Limited, has filed four patent
applications with the UK government’s Intellectual Property Office.
The applications cover three cannabinoid formulations known as MRX1, MRX2 and its most recently
invented formulation MRX3. These formulations are being developed as cannabidiol-based
medicines for the treatment of a number of complex inflammatory indications which are unmet by
existing treatments. The fourth application covers a proprietary method for formulating these
products.
The MRX1 formulation is to be used as the Active Pharmaceutical Ingredient (API) in two upcoming
Phase II Randomised Control Trials (RCTs) to be conducted by the University of Edinburgh. One trial
is investigating the effect of cannabidiol on chemotherapy induced peripheral neuropathy (CIPN)
and the other is investigating the effect of cannabidiol on endometriosis.
Ananda’s CEO, Melissa Sturgess, commented: “The filing of these patent applications is an important
step as we build Ananda. The patent applications will protect the Company’s intellectual property and
help to build value for shareholders.”
